Case	Court	Filed	Status	Judge
DOW PHARMACEUTICAL SCIENCES, INC. et al v. TARO PHARMACEUTICALS U.S.A., INC. et al 2:2017cv00544 1 patentANDA 208683benzoyl peroxide and clindamycin phosphate	D.N.J.	2017-01-26	Terminated 2017-04-20	—
DOW PHARMACEUTICAL SCIENCES, INC. et al v. TARO PHARMACEUTICALS U.S.A., INC. et al 2:2016cv00217 1 patentANDA 208683benzoyl peroxide and clindamycin phosphate	D.N.J.	2016-01-12	Terminated 2018-10-24	—
Dow Pharmaceutical Sciences, Inc. et al v. Tolmar, Inc. 1:2015cv01030 2 patentsANDA 207194clindamycin phosphate and benzoyl peroxide	D. Del.	2015-11-06	Terminated 2016-05-23	—
DOW PHARMACEUTICAL SCIENCES, INC. et al v. PERRIGO COMPANY et al 2:2013cv06922 1 patentANDA 205397clindamycin phosphate and benzoyl peroxide	D.N.J.	2013-11-15	Terminated 2014-08-28	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Acanya (2023)

Total Spending

$14K

Total Claims

Beneficiaries

—

Avg Cost/Unit

$11.11

Spending Trend

$61K(2019)→$34K(2020)→$16K(2021)→$10K(2022)→$14K(2023)

YoY Change:+0.7%

5yr CAGR:+1.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

7 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 2.5%;EQ 1.2% BASE

RLDAB

6 patents0 exclusivities▴

GEL;TOPICAL | Approved: Oct 23, 2008

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8288434	Aug 5, 2029	—	—	Yes		—
8663699	Jun 3, 2029	—	—	—		—
8895070	Jun 3, 2029	—	—	—		—
9078870	Jun 3, 2029	—	—	Yes	—	—
10220049	Jun 3, 2029	—	—	Yes		—
10624918	Jun 3, 2029	—	—	—		—

#002 — 3.75%;EQ 1.2% BASE

RLDAB

5 patents0 exclusivities▾

GEL;TOPICAL | Approved: Nov 24, 2014